Disc Medicine to Participate in Upcoming Investor Conferences

Rhea-AI Summary

Disc Medicine (NASDAQ:IRON), a clinical-stage biopharmaceutical company focusing on hematologic diseases, has announced its participation in four upcoming investor conferences in September 2024. The company's management will engage in fireside chats at the following events:

• 2024 Wells Fargo Securities Healthcare Conference (Sept. 6, 10:15 a.m. ET)
• Morgan Stanley 22nd Annual Global Healthcare Conference (Sept. 6, 1:05 p.m. ET)
• H.C. Wainwright 26th Annual Global Investment Conference (Sept. 11, 9:30 a.m. ET)
• 2024 Cantor Global Healthcare Conference (Sept. 19, 8:00 a.m. ET)

Live webcasts of these fireside chats will be accessible through Disc Medicine's investor relations website, with archived replays available after each event.

News Market Reaction – IRON

+4.14%

+4.14% Session move

In the trading session that priced this news, IRON gained 4.14%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

WATERTOWN, Mass., Aug. 30, 2024 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, announced today that company management will participate in fireside chats at four upcoming investor conferences:

• 2024 Wells Fargo Securities Healthcare Conference on Friday, September 6^th at 10:15 a.m. ET.
• Morgan Stanley 22^nd Annual Global Healthcare Conference on Friday, September 6^th at 1:05 p.m. ET.
• H.C. Wainwright 26^th Annual Global Investment Conference on Wednesday, September 11^th at 9:30 a.m. ET.
• 2024 Cantor Global Healthcare Conference on Thursday, September 19^th at 8:00 a.m. ET.

A live webcast of the fireside chats will be available through the investor relations section of the Company's website at ir.discmedicine.com and an archived replay will be available after the event.

About Disc Medicine

Disc Medicine (NASDAQ:IRON) is a clinical-stage biopharmaceutical company committed to discovering, developing, and commercializing novel treatments for patients who suffer from serious hematologic diseases. We are building a portfolio of innovative, potentially first-in-class therapeutic candidates that aim to address a wide spectrum of hematologic diseases by targeting fundamental biological pathways of red blood cell biology, specifically heme biosynthesis and iron homeostasis. For more information, please visit www.discmedicine.com.

Media Contact

Peg Rusconi
Deerfield Group
peg.rusconi@deerfieldgroup.com

Investor Relations Contact

Christina Tartaglia
Precision AQ
christina.tartaglia@precisionaq.com

FAQ

What investor conferences will Disc Medicine (IRON) participate in during September 2024?

Disc Medicine (IRON) will participate in four investor conferences in September 2024: Wells Fargo Securities Healthcare Conference, Morgan Stanley Global Healthcare Conference, H.C. Wainwright Global Investment Conference, and Cantor Global Healthcare Conference.

When is Disc Medicine's (IRON) fireside chat at the Wells Fargo Securities Healthcare Conference?

Disc Medicine's (IRON) fireside chat at the Wells Fargo Securities Healthcare Conference is scheduled for Friday, September 6, 2024, at 10:15 a.m. ET.

How can investors access Disc Medicine's (IRON) fireside chat webcasts?

Investors can access live webcasts of Disc Medicine's (IRON) fireside chats through the investor relations section of the company's website at ir.discmedicine.com. Archived replays will be available after each event.

What is Disc Medicine's (IRON) focus as a biopharmaceutical company?

Disc Medicine (IRON) is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases.